Non-small-cell lung cancer
Pro Research Analysisby 
Searched over 200M research papers
Epidemiology and Risk Factors of Non-Small-Cell Lung Cancer (NSCLC)
Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is a leading cause of cancer-related deaths worldwide. The main risk factor for NSCLC is tobacco smoking, but other contributors include radon exposure, air pollution, and genetic predispositions. Most patients are diagnosed at an advanced stage due to late symptom onset and insufficient screening programs, resulting in a poor overall prognosis Gridelli2015Duma2019Zappa2016+1 MORE.
Advances in Screening and Early Detection for NSCLC
Recent years have seen significant progress in early detection of NSCLC. Low-dose computed tomography (CT) screening in high-risk populations has been shown to reduce lung cancer mortality by 20% and all-cause mortality by 6.7%, enabling earlier diagnosis and improved outcomes Duma2019Zappa2016Herbst2018+1 MORE. Advances in imaging and less invasive diagnostic techniques, such as endoscopy-based and image-based methods, have also contributed to better staging and management Herbst2018Wang2021.
Diagnostic Approaches and Staging in NSCLC
Diagnosis of NSCLC typically involves imaging techniques like X-ray, CT, and PET scans, followed by histological examination of tumor biopsies. Accurate staging is crucial for determining the most effective treatment strategy, as it guides the choice between surgery, radiotherapy, chemotherapy, and systemic therapies Gridelli2015Herbst2018Wang2021.
Treatment Strategies for NSCLC: Surgery, Radiotherapy, and Chemotherapy
Treatment options for NSCLC depend on the stage at diagnosis. Early-stage disease may be managed with surgery and/or radiotherapy, while locally advanced cases often require multimodal approaches, including chemoradiotherapy. New surgical and radiotherapeutic techniques have improved outcomes, especially when combined with perioperative and adjuvant therapies Duma2019Goldstraw2011Herbst2018+1 MORE.
Targeted Therapies and Immunotherapy in NSCLC
The introduction of targeted therapies, such as tyrosine kinase inhibitors (TKIs) for tumors with EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK mutations, has transformed the treatment landscape for NSCLC. These therapies have led to significant survival benefits in selected patients Zappa2016Ettinger2022Alexander2020+3 MORE. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has also become a cornerstone of NSCLC management, either as monotherapy, in combination with chemotherapy, or after chemoradiotherapy in unresectable stage III disease Zappa2016Ettinger2022Alexander2020+2 MORE.
The Role of Biomarkers and Personalized Medicine in NSCLC
Biomarker testing, including the assessment of programmed cell death protein-ligand 1 (PD-L1) expression and identification of actionable genetic mutations, is now essential for guiding therapy selection in NSCLC. However, PD-L1 alone is not always a reliable predictor of response to immunotherapy, highlighting the need for more accurate predictive biomarkers to optimize personalized treatment approaches Zappa2016Goldstraw2011Alexander2020+2 MORE.
Ongoing Challenges and Future Directions in NSCLC Management
Despite advances, most patients with advanced NSCLC eventually develop resistance to current therapies, and overall cure rates remain low, especially in metastatic disease. Continued research into new drugs, combination therapies, and robust predictive biomarkers is needed to further improve outcomes and expand the benefits of treatment to a broader patient population Duma2019Ettinger2022Reck2013+1 MORE. Palliative care remains a key component of management, significantly enhancing quality of life for patients with advanced disease .
Conclusion
NSCLC remains a major global health challenge, but recent advances in screening, diagnostics, targeted therapies, and immunotherapy have improved patient outcomes and survival. Ongoing research and the integration of personalized medicine approaches are essential to address remaining challenges and further enhance the management of NSCLC Duma2019Zappa2016Goldstraw2011+3 MORE.
Sources and full results
Most relevant research papers on this topic